ERBB2 and breast cancer: Understanding the correlation between APIS BC Subtyping Kit ERBB2 mRNA expression and the response to anti-HER2 treatments could aid in stratifying patients into responder and non-responder groups, potentially reducing unnecessary severe side effects and offering a more personalized treatment approach.